The therapeutic effects and applicability of the use of Cannabidiol in patients with Alzheimer's disease

Authors

DOI:

https://doi.org/10.33448/rsd-v14i2.48329

Keywords:

Cannabidiol; Alzheimer's; Therapy.

Abstract

Cannabis has been studied for its therapeutic potential, especially in the treatment of neurodegenerative diseases such as Alzheimer's, due to the neuroprotective, anti-inflammatory and antioxidant effects of cannabinoids. The endocannabinoid system, which includes CB1 and CB2 receptors, plays a crucial role in regulating physiological and behavioral functions. The objective of this research is to better understand the ability of cannabinoids to modulate this excitotoxic pathway, positioning them as potential therapeutic agents that can offer protection against the degenerative effects of AD.. The review followed ethical resolution no. 466/2012, using public domain data and was carried out in the MEDLINE/PubMed databases between January and March 2024. 52 articles were selected, of which 5 met the inclusion criteria, focusing on studies published between 2018 and 2024. These studies indicated that CBD has a positive impact on the treatment of the disease, helping to modulate pathological mechanisms and improving cognitive and neuropsychiatric symptoms. Among the approaches studied, cannabis was effective in relieving symptoms such as agitation and behavioral disorders, as well as benefits in rigidity and cognitive scores. CBD has shown protective effects against oxidative stress, and molecular modeling has suggested that compounds from Cannabis sativa may interact with therapeutic targets for Alzheimer's disease. Despite the positive results, the review highlights the need for more research and overcoming legal barriers to ensure the effectiveness and safety of medicinal cannabis in the treatment of Alzheimer's.

References

Abate, G., Uberti, D., & Tambaro, S. (2021). Potential and limits of cannabinoids in Alzheimer’s disease therapy. Biology, 10(6), 542. https://doi.org/10.3390/biology10060542

Antonsdottir, I. M., Makino, K. M., & Porsteinsson, A. P. (2016). Dazed and confused: Medical cannabis in Alzheimer disease. The American Journal of Geriatric Psychiatry, 24(11), 1004–1006. https://doi.org/10.1016/j.jagp.2016.07.004

Bahji, A., et al. (2019). Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis. The Canadian Journal of Psychiatry, 65(6). https://doi.org/10.1177/0706743719892717

Barbosa, A., et al. (2020). O uso do composto de Canabidiol no tratamento da doença de Alzheimer (revisão da literatura). Research, Society and Development, 9(8), e442986073. https://rsdjournal.org/index.php/rsd/article/download/6073/5023/27743

Bastos, M., et al. (2023). Factors associated with Alzheimer’s disease prevalence and mortality in Brazil – An ecological study. PLOS One, 18(8), e0283936. https://doi.org/10.1371/journal.pone.0283936

Bhunia, S., et al. (2022). Cannabidiol for neurodegenerative disorders: A comprehensive review. Frontiers in Pharmacology, 13, 989717. https://doi.org/10.3389/fphar.2022.989717

Bonini, S. A., et al. (2018). Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of Ethnopharmacology, 227, 300–315. https://doi.org/10.1016/j.jep.2018.09.013

Casarin, S. T. et al. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health. Journal of Nursing and Health. 10 (5). https://periodicos.ufpel.edu.br/index.php/enfermagem/article/view/19924.

Cheng, D., et al. (2014). Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice. Psychopharmacology, 231(15), 3009–3017. https://doi.org/10.1007/s00213-014-3583-x

Coles, M., et al. (2020). Medium-dose chronic cannabidiol treatment reverses object recognition memory deficits of APPswe/PS1ΔE9 transgenic female mice. Frontiers in Pharmacology, 11, 587604. https://doi.org/10.3389/fphar.2020.587604

Coory, R., Gupta, V., & Suphioglu, C. (2020). Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: A review. Molecular Neurobiology, 57(11), 4878–4890. https://doi.org/10.1007/s12035-020-02175-3

Elsohly, M. A., et al. (2017). Phytochemistry of Cannabis sativa L. In A. D. Kinghorn, et al. (Eds.), Phytocannabinoids (pp. 1-36). Springer International Publishing. https://doi.org/10.1007/978-3-319-44756-0_1

Henriques, J. (2023). Cannabis and cannabinoids’ therapeutic applications and safety – a literature review. Repositório Aberto. https://repositorio-aberto.up.pt/bitstream/10216/121337/2/343772.pdf

Li, S., et al. (2023). Impact of the cannabinoid system in Alzheimer’s disease. Current Neuropharmacology, 21(3), 715–726. https://doi.org/10.2174/1570159X20666230317142138

Patil, N., et al. (2023). Investigation of Cannabis sativa phytochemicals as anti-Alzheimer’s agents: An in silico study. Plants, 12(3), 510. https://doi.org/10.3390/plants12030510

Paschalidis, M., et al. (2023). Tendência de mortalidade por doença de Alzheimer no Brasil, 2000 a 2019. Epidemiologia e Serviços de Saúde, 32(2), e2022886. https://doi.org/10.1590/S2237-96222023000200002

Peprah, K., & McCormack, S. (2019). Medical cannabis for the treatment of dementia: A review of clinical effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health.

Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM. Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paul. Enferm. 20 (2). https://doi.org/10.1590/S0103-21002007000200001.

Watt, G., & Karl, T. (2017). In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease. Frontiers in Pharmacology, 8, 106. https://doi.org/10.3389/fphar.2017.00106

Downloads

Published

26/02/2025

How to Cite

COUTINHO, F. S.; COELHO, E. C. F.; ROCHA, T. G.; SOUSA, D. B. de; FREIRE , R. S.; SANTOS, G. C.; BLANCH, G. T. The therapeutic effects and applicability of the use of Cannabidiol in patients with Alzheimer’s disease. Research, Society and Development, [S. l.], v. 14, n. 2, p. e11814248329, 2025. DOI: 10.33448/rsd-v14i2.48329. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/48329. Acesso em: 30 may. 2025.

Issue

Vol. 14 No. 2

Section

Health Sciences

License

Copyright (c) 2025 Fernanda Silva Coutinho; Eduardo Chaves Ferreira Coelho; Taís Garcia Rocha; Danilo Borges de Sousa; Ricardo Silva Freire ; Gabriel Cerqueira Santos; Graziela Torres Blanch

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.